The glaucoma subtypes treated included primary open-angle glaucoma (n = 51); exfoliation glaucoma (n = 24); chronic angle closure glaucoma (n = 15); and congenital/juvenile glaucoma (n = 5). The results were as follows.
The mean preoperative IOP was 25.1 ± 5.3 mm Hg, and the mean postoperative IOP at 12 months was 17.5 ± 5.1 mm Hg (P = 0.004).
The mean number of IOP-lowering medications used preoperatively was 3.0 ± 1.1; the mean number of medications used at the 12 month postoperative visit was 1.4 ± 1.0 (P = 0.03).
Twenty-two patients received at least one re-treatment with an increase in energy; eight patients had three rounds of treatment, four patients had four rounds of treatment and one patient had five rounds.
The mean preoperative IOP in this study was lower and more analogous to what I see in my daily practice in comparison to that of a previous investigation using micropulse TSCPC,2 which was conducted on a more mature and severely diseased population.
This study suggests the device does not need to be reserved as a treatment of last resort; it can be utilised as an effective therapy earlier than where traditional algorithms may place it.